First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)

被引：0
|
作者：
Lorenzi, M. [1 ]
Dal Maso, A. [1 ]
Ferro, A. [1 ]
Polo, V. [2 ]
Scattolin, D. [1 ]
Macerelli, M. [3 ]
Follador, A. [3 ]
Targato, G. [3 ]
Indraccolo, S. [4 ]
Frega, S. [5 ]
Menis, J. [1 ]
Bonanno, L. [5 ]
Guarneri, V. [1 ]
Conte, P. F. [1 ]
Pasello, G. [1 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[2] Ca Foncello Hosp, Oncol Unit, AULSS 2 Marca Trevigiana, Treviso, Italy
[3] Azienda Sanit Univ Integrata Udine, Santa Maria Misericordia Hosp, Dept Med Oncol, Udine, Italy
[4] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy
[5] Veneto Inst Oncol IOV IRCCS, Div Med Oncol 2, Padua, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149P
引用
收藏
页码：S779 / S779
页数：1
相关论文
共 50 条
  • [21] Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations
    Pham Van Luan
    Nguyen Dinh Tien
    Nguyen Minh Hai
    Nguyen Dao Tien
    Thi Thi Duyen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [22] A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
    Nieva, J.
    Karia, P. S.
    Okhuoya, P.
    Berktas, M.
    Salomonsen, R. J-B.
    Servidio, L.
    Chapaneri, J.
    De Silva, K.
    Martin, E.
    Griesinger, F.
    ANNALS OF ONCOLOGY, 2023, 34
  • [23] Real-world treatment patterns before and after receiving PD-L1 test results in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
    Antonia, S. J.
    Wu, N.
    Ge, W.
    Pouliot, J-F.
    Dietz, H.
    Jalbert, J.
    Quek, R. G.
    Harnett, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1419 - S1420
  • [24] Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
    VanderWalde, A. M.
    Lee, J.
    Tolba, K.
    Ward, A.
    Cooper, M.
    Huang, R. S. P.
    Venstrom, J.
    Oxnard, G.
    Schrock, A. B.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1006 - S1007
  • [25] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
    Cronin-Fenton, D.
    Dalvi, T.
    Hedgeman, E.
    Norgaard, M.
    Petersen, L.
    Hansen, H.
    Fryzek, J.
    Lawrence, D.
    Walker, J.
    Mellemgaard, A.
    Rasmussen, T.
    Shire, N.
    Rigas, J.
    Potter, D.
    Hamilton-Dutoit, S.
    Sorensen, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085
  • [26] Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
    Hisashi Tanaka
    Kageaki Taima
    Masamichi Itoga
    Yoshiko Ishioka
    Keisuke Baba
    Toshihiro Shiratori
    Hiroaki Sakamoto
    Junichiro Tsuchiya
    Hideyuki Nakagawa
    Yukihiro Hasegawa
    Hideo Yasugahira
    Koichi Okudera
    Shingo Takanashi
    Sadatomo Tasaka
    Medical Oncology, 2019, 36
  • [27] Afatinib as First-Line Treatment in Elderly Patients with EGFR-Mutant Non-Small Cell Lung Cancer: Real-World Data Analysis
    Chen, Yen-Ting
    Yen, Chia-Te
    Wu, Wen-Jui
    Yang, Sheng-Hsiung
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2022, 16 (03) : 266 - 270
  • [28] Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Itoga, Masamichi
    Ishioka, Yoshiko
    Baba, Keisuke
    Shiratori, Toshihiro
    Sakamoto, Hiroaki
    Tsuchiya, Junichiro
    Nakagawa, Hideyuki
    Hasegawa, Yukihiro
    Yasugahira, Hideo
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [29] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
    Cheng, Wen-Chien
    Lin, Chi-Chien
    Liao, Wei-Chih
    Lin, Yu-Chao
    Chen, Chia-Hung
    Chen, Hung-Jen
    Tu, Chih-Yen
    Hsia, Te-Chun
    BMC CANCER, 2024, 24 (01)
  • [30] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
    Wen-Chien Cheng
    Chi-Chien Lin
    Wei-Chih Liao
    Yu-Chao Lin
    Chia-Hung Chen
    Hung-Jen Chen
    Chih-Yen Tu
    Te-Chun Hsia
    BMC Cancer, 24
12345